Moreover, silencing NEK2 was demonstrated to sensitize triple-negative breast cancer cells to paclitaxel and doxorubicin [37], which indicated that NEK2 may be potential therapeutic target for breast cancer. Here, NEK2 is linked to triple-negative breast carcinoma.